MGAT2

MGAT2 encodes a Golgi-resident UDP-GlcNAc:α-6-D-mannoside β-1,2-N-acetylglucosaminyltransferase II (GnT II) that catalyzes a committed step in converting oligomannose N-glycans to complex-type N-glycans, a modification essential for gastrointestinal, hematologic, and skeletal development as well as immune glycoantigen presentation and spermatogenesis (PMID:7635144, PMID:12417412, PMID:24310166, PMID:39364139). Loss-of-function mutations in the catalytic domain cause carbohydrate-deficient glycoprotein syndrome type II (CDG-IIa) (PMID:8808595). The same gene symbol also designates acyl-CoA:monoacylglycerol acyltransferase 2 (MOGAT2), an ER-localized enzyme that acylates monoacylglycerols to diacylglycerols in the intestinal monoacylglycerol pathway of triglyceride re-synthesis; it physically interacts with DGAT2 via DGAT2's transmembrane domains to channel diacylglycerol toward triacylglycerol storage, and its enterocyte activity controls dietary fat absorption, postprandial GIP secretion, and systemic energy expenditure (PMID:12621063, PMID:25164810, PMID:19732742, PMID:21734185).

1. 1995 High

   Establishing that MGAT2 encodes a type II membrane glycosyltransferase (GnT II) with defined domain architecture and catalytic activity resolved the identity of the enzyme responsible for the key N-glycan branching step.

   Evidence Baculovirus expression and purification from Sf9 cells with product confirmed by NMR and mass spectrometry

   PMID:7635144

   Open questions at the time

   • Substrate specificity determinants within the catalytic domain were not mapped
   • Oligomeric state of the enzyme in the Golgi was unknown
2. 1996 High

   Identifying point mutations in GnT II that abolish enzyme activity in CDG-IIa patients established the gene as causative for this congenital disorder of glycosylation and defined critical catalytic-domain residues.

   Evidence Patient mutation identification with functional validation in baculovirus/insect cell expression system; family analysis by restriction endonuclease digestion

   PMID:8808595

   Open questions at the time

   • Structural basis for how individual substitutions inactivate catalysis was not determined
   • Genotype-phenotype correlation across CDG-IIa spectrum was unexplored
3. 1998 Medium

   Characterization of the MGAT2 promoter revealed a TATA-less, Sp1/CCAAT-driven architecture and later identified Ets-factor regulation, distinguishing its transcriptional control from that of GnT V.

   Evidence 5'-RACE, RNase protection, promoter-CAT reporter deletion series in HeLa cells; Ets co-transfection and mobility-shift assays

   PMID:10749681 PMID:9579808

   Open questions at the time

   • Tissue-specific regulation (e.g., intestine vs. lymphoid) was not addressed
   • In vivo relevance of Ets-mediated activation was not tested
4. 2002 High

   Homozygous Mgat2 knockout demonstrated that GnT II is indispensable for complex N-glycan synthesis in vivo, with loss causing multi-organ developmental defects and neonatal lethality.

   Evidence Constitutive knockout mouse with enzyme activity assay and N-glycan structural analysis

   PMID:12417412

   Open questions at the time

   • Cell-type-specific contributions to the lethal phenotype were undefined
   • Compensatory glycosylation pathways were not characterized
5. 2003 High

   Cloning and biochemical characterization of MGAT2 as a monoacylglycerol acyltransferase established a second, metabolically distinct function: the enzyme acylates monoacylglycerols to diacylglycerols and possesses intrinsic DGAT activity separable by detergent treatment.

   Evidence Heterologous expression in insect cells, COS-7, and E. coli with in vitro activity assays using various acyl-CoA and MAG substrates

   PMID:12576479 PMID:12621063 PMID:12730219

   Open questions at the time

   • Whether the glycosyltransferase (GnT II) and acyltransferase (MOGAT2) are truly the same gene product or distinct loci was initially confusing in the literature
   • Structural basis for dual MGAT/DGAT activity was not resolved
6. 2009 High

   Demonstrating that enterocyte MGAT2 is required for efficient triglyceride re-synthesis and chylomicron secretion, which in turn drives postprandial GIP release, placed the enzyme at a critical control point in dietary fat absorption and incretin signaling.

   Evidence Mogat2 knockout mouse with oral triglyceride loading and plasma lipid/gut hormone measurements

   PMID:19732742

   Open questions at the time

   • Whether MGAT2 loss alters enterocyte lipid droplet dynamics was not examined
   • Contribution of other MGAT isoforms to residual activity was not quantified
7. 2011 High

   Finding that MGAT2-deficient mice have increased energy expenditure independent of fat malabsorption revealed an unexpected systemic metabolic role beyond intestinal lipid processing.

   Evidence Mogat2 knockout crossed to Agouti obese mice, metabolic cage calorimetry under multiple dietary conditions

   PMID:21734185

   Open questions at the time

   • Tissue(s) responsible for increased energy expenditure were not identified
   • Molecular mechanism linking MGAT2 loss to elevated metabolic rate remains unknown
8. 2013 High

   Myeloid-specific Mgat2 ablation showed that GnT II-dependent complex N-glycans on antigen-presenting cells are specifically required for glycoantigen presentation and T cell activation, separating this function from protein-antigen processing.

   Evidence LyzM-Cre conditional knockout with in vitro and in vivo T cell activation assays comparing glyco- vs. protein antigens

   PMID:24310166

   Open questions at the time

   • Identity of the N-glycoprotein(s) on APCs whose glycosylation is critical for glycoantigen presentation was not determined
   • Whether this affects anti-bacterial immunity in vivo was not tested
9. 2014 High

   Demonstrating a direct physical interaction between MGAT2 and DGAT2 dependent on DGAT2's transmembrane domains provided a channeling mechanism for diacylglycerol flux toward triacylglycerol synthesis in the ER and on lipid droplets.

   Evidence Co-immunoprecipitation, in situ proximity ligation assay, chemical cross-linking, deletion mutagenesis, and co-localization imaging

   PMID:25164810

   Open questions at the time

   • Stoichiometry and structural architecture of the MGAT2–DGAT2 complex were not resolved
   • Whether the interaction is regulated by metabolic signals was not tested
10. 2024 Medium

    Conditional deletion in spermatogonia revealed that MGAT2-generated complex N-glycans are required for spermatogenesis by restraining AKT/ERK signaling, while live-cell NanoBiT imaging demonstrated that MGAT2 (GnT II) forms homo- and heterodimers with MGAT1 during ER-to-Golgi transit.

    Evidence Stra8-iCre conditional knockout with signaling analysis; NanoBiT split-luciferase complementation with bioluminescence microscopy

    PMID:39083973 PMID:39364139

    Open questions at the time

    • How complex N-glycans suppress AKT/ERK in germ cells is mechanistically unresolved
    • Functional consequence of MGAT1–MGAT2 heterodimerization on catalytic activity was not tested
    • Findings from single labs, not yet independently replicated

• No structural model of MGAT2 (GnT II) at atomic resolution exists, the mechanism linking MGAT2 loss to increased energy expenditure is unknown, and the functional significance of MGAT1–MGAT2 heterodimerization remains untested.
• Atomic structure of the catalytic domain has not been solved
• Tissue-specific mediators of the energy expenditure phenotype are unidentified
• Regulatory inputs that modulate MGAT2 enzymatic activity in vivo are poorly defined